As Nigerians continue to suffer from malaria on a daily basis, Geneith Pharmaceuticals Limited has reiterated its commitment to guaranteeing reliable treatment options. The company recently made the pledge while urging responsible drug use to ensure effective outcomes.
In a press statement signed by the company’s Chairman, Chief Emmanuel Umenwa, Geneith Pharmaceuticals Limited disclosed that even though progress has been made in malaria control thus far, problems persist amid the widespread misuse of medications, mostly fuelled by misconceptions about side effects.
According to the Assistant General Manager, Sales and Marketing at Geneith Pharmaceuticals, Pharm. Abimbola Bowoto, Nigerians should know that side effects, whether mild or rare, are very much normal when it comes to medicine use all across the globe.
Insisting that adhering to medical advice decreases risks and improves therapeutic benefits, he stated that antimalarial therapies like Camosunate, a reliable Artemisinin-based Combination Therapy (ACT) that combines Artesunate and Amodiaquine, helps to combat malaria effectively.
“Camosunate remains one of Nigeria’s most dependable ACTs for uncomplicated malaria, in full alignment with World Health Organization (WHO) recommendations. Its proven efficacy lies in its ability to clear parasites rapidly, relieve symptoms promptly, and offer extended protection due to the long half-life of Amodiaquine,” he said.
Referencing a 2013 clinical research carried out at the University of Benin Teaching Hospital (UBTH), Bowoto affirmed Camosunate’s potency and safety in both adult and paediatric patients, promising high cure rates, minimal side effects and strong compliance when the product is used as recommended.
The study further highlighted improved outcomes when Camosunate was used with meals and proper hydration, advice that fully aligns with Geneith’s product guidelines and patient information leaflets.
Announcing that taking Camosunate after food with sufficient water boosts absorption and reduces discomfort, the General Manager emphasized that a lot of negative side effects happen when patients fail to follow usage directions.
Bowoto noted that Geneith’s commitment to integrity and innovation remains firm, and the company will keep driving its pursuit of excellence in quality and safety.
He concluded by advocating for stronger public awareness on proper medicine use, urging healthcare providers to keep prescribing WHO-compliant ACTs such as Camosunate and advising patients to always complete their treatment courses to avoid relapse and drug resistance.
“Geneith’s mission goes beyond producing medicines; it is about protecting trust, advancing innovation, and standing firmly with healthcare professionals and communities in the fight against malaria,” he added.
Folami David is a dynamic journalist who views the world through an analytical lens, translating complex narratives across multiple industries into compelling stories. With an insatiable appetite for information and a keen eye for emerging trends, Folami specializes in uncovering the interconnections between technology, business, culture, and society.
